Javascript must be enabled to continue!
FORMULATION AND EVALUATION OF LOSARTAN POTASSIUM MATRIX TABLETS BY USING DIFFERENT POLYMERS
View through CrossRef
The study aims to create a sustained release matrix tablet for Losartan potassium, an angiotensin II receptor antagonist, to improve patient compliance and maintain therapeutic blood or tissue levels for extended periods. The research investigates the role of novel semi-synthetic polymers and natural polymers in comparison to well-known release retarding agents. Gastroretentive drug delivery systems (GRDDS) are unique technologies designed to improve drug bioavailability and absorption by avoiding the first-pass effect. Losartan potassium, an angiotensin II receptor antagonist, has a bioavailability of 32% and a low elimination half-life, making it suitable for oral controlled release. The study utilized natural and synthetic polymers in matrix tablet preparation, concentration, drug particles size, additives, and excipients to modify drug release. The powder mixtures were tested for pre-compression parameters and post-compression parameters, and in-vitro dissolution studies showed good dissolution profiles for drug release. Formulations with higher concentrations and polymers sustained drug release for 24 hours. FT-IR Spectroscopy confirmed drug compatibility with polymers and other excipients
KEYWORDS: matrix tablets, Losartan Potassium, flow properties, pre compression parameters post compression parameters, In-vitro dissolution.
Title: FORMULATION AND EVALUATION OF LOSARTAN POTASSIUM MATRIX TABLETS BY USING DIFFERENT POLYMERS
Description:
The study aims to create a sustained release matrix tablet for Losartan potassium, an angiotensin II receptor antagonist, to improve patient compliance and maintain therapeutic blood or tissue levels for extended periods.
The research investigates the role of novel semi-synthetic polymers and natural polymers in comparison to well-known release retarding agents.
Gastroretentive drug delivery systems (GRDDS) are unique technologies designed to improve drug bioavailability and absorption by avoiding the first-pass effect.
Losartan potassium, an angiotensin II receptor antagonist, has a bioavailability of 32% and a low elimination half-life, making it suitable for oral controlled release.
The study utilized natural and synthetic polymers in matrix tablet preparation, concentration, drug particles size, additives, and excipients to modify drug release.
The powder mixtures were tested for pre-compression parameters and post-compression parameters, and in-vitro dissolution studies showed good dissolution profiles for drug release.
Formulations with higher concentrations and polymers sustained drug release for 24 hours.
FT-IR Spectroscopy confirmed drug compatibility with polymers and other excipients
KEYWORDS: matrix tablets, Losartan Potassium, flow properties, pre compression parameters post compression parameters, In-vitro dissolution.
Related Results
Losartan Monotherapy vs Combination Regimens in IgA Nephropathy: A Systematic Review and Network Meta-analysis
Losartan Monotherapy vs Combination Regimens in IgA Nephropathy: A Systematic Review and Network Meta-analysis
Background: IgA nephropathy (IgAN) is a disorder in which Immunoglobulin A (IgA) antibodies build up, causing kidney damage. Losartan, an Angiotensin Receptor Blocker (ARB), has sh...
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension
Background: Candesartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker (ARB). Several clinical trials have compared candesartan with losartan in t...
Evaluation of Losartan Usage in a Regional Hospital in Hong Kong
Evaluation of Losartan Usage in a Regional Hospital in Hong Kong
Objective: To determine whether losartan usage follows the hospital's guidelines in terms of indications and reasons for use and to assess the accuracy of physicians in completing ...
Losartan and magnesium sulfate administration reduce gentamicin-induced nephrotoxicity in rat model
Losartan and magnesium sulfate administration reduce gentamicin-induced nephrotoxicity in rat model
Background: Nephrotoxicity is the most known side effect of gentamicin. In addition, renin angiotensin system (RAS) plays an important role in the pathogenesis of renal injury and ...
Losartan reduces collagen content and intimal thickening of iliac arteries after balloon injury in rabbits
Losartan reduces collagen content and intimal thickening of iliac arteries after balloon injury in rabbits
Intimal thickening and formation of extracellular matrix are parts of the repair process after vascular injury. Similar processes occur after coronary angioplasty. Prior studies ha...
Impact of Losartan on Portal hypertension and Liver Cirrhosis: A Systematic Review
Impact of Losartan on Portal hypertension and Liver Cirrhosis: A Systematic Review
Abstract
Background
Portal hypertension, a complication of chronic liver disease, results from elevated pressure between the po...
Losartan: A Pharmacotherapy in Cardiovascular Disease
Losartan: A Pharmacotherapy in Cardiovascular Disease
Background:
A recently published article confirmed that in 2019, around 523 million people suffered from cardiovascular disease (including 18.6 million deaths) worldwide. Losartan,...
Losartan to reduce inflammation and fibrosis endpoints in HIV disease
Losartan to reduce inflammation and fibrosis endpoints in HIV disease
Background:
Persistent inflammation and incomplete immune recovery among persons with HIV (PHIV) are associated with increased disease risk. We hypothesized that the an...

